Metraipolis › archive › dc_e8be7436f196

Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis — Europe PMC PMID:42535103

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42535103
DOI
10.1155/joos/2813928
License (as archived)
solo-consultazione
Archived
2026-10-17T08:05:20.558Z
SHA-256 of the archived text
4db88ed347bd808f147d72c56a9742c19e04b2e9f34d60bb12189442ad6425d7
Stable URL of this page
https://metraipolis.com/documento/dc_e8be7436f196

How to cite

Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis — Europe PMC PMID:42535103 — Europe PMC (en), https://europepmc.org/article/MED/42535103 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e8be7436f196 (Metraipolis archive dc_e8be7436f196, sha256 4db88ed347bd808f147d72c56a9742c19e04b2e9f34d60bb12189442ad6425d7)
BibTeX
@misc{dce8be7436f196,
  title = {Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis — Europe PMC PMID:42535103},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42535103},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e8be7436f196; sha256 4db88ed347bd808f147d72c56a9742c19e04b2e9f34d60bb12189442ad6425d7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42535103. Agents can read the archived copy with the MCP tool read_document.